Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment

Toxicology and Applied Pharmacology

Volumn 279, Issue 3, 2014, Pages 467-476

  Liu, Nanjun ^a   Tengstrand, Elizabeth A ^a   Chourb, Lisa ^a   Hsieh, Frank Y ^a  

^a Nextcea Inc   (United States)

Author keywords

Biomarker; Bis(monoacylglycerol)phosphate; Di 22:6 BMP; Di docosahexaenoyl (22:6) bis(monoacylglycerol)phosphate; Drug induced phospholipidosis; Safety assessment

Indexed keywords

AMIODARONE; CHLOROQUINE; DI 22:6 BIS(MONOACYLGLYCEROL)PHOSPHATE; LIPID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CREATININE; LYSOBISPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; MONOACYLGLYCEROL; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DOG; FEMALE; HAPLORHINI; HUMAN; LAMELLAR BODY; LIPIDOSIS; MALE; MOUSE; NIEMANN PICK DISEASE; NONHUMAN; RAT; RISK ASSESSMENT; SERODIAGNOSIS; URINALYSIS; ADVERSE DRUG REACTION; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DI-22:6-BMP; DI-DOCOSAHEXAENOYL (22:6) BIS(MONOACYLGLYCEROL)PHOSPHATE; DRUG DESIGN; DRUG-INDUCED PHOSPHOLIPIDOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MACACA FASCICULARIS; METABOLISM; REFERENCE VALUE; REPRODUCIBILITY; SPECIES DIFFERENCE; URINE; WISTAR RAT;

BIOMARKER; BIS(MONOACYLGLYCEROL)PHOSPHATE; DI-22:6-BMP; DI-DOCOSAHEXAENOYL (22:6) BIS(MONOACYLGLYCEROL)PHOSPHATE; DRUG-INDUCED PHOSPHOLIPIDOSIS; SAFETY ASSESSMENT;

ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DOGS; DRUG DESIGN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; LIPIDOSES; LYSOPHOSPHOLIPIDS; MACACA FASCICULARIS; MALE; MICE; MONOGLYCERIDES; PHOSPHOLIPIDS; RATS; RATS, WISTAR; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY;

EID: 84907171740     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.06.014     Document Type: Article

References (87)

1. Adams P.C., Holt D.W., Storey G.C.A., Morley A.R., Callaghan J., Campbell R.W. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 1985, 72(5):1064-1075.
2. Ahn J., Wee W.R., Lee J.H., Hyon J.Y. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J. Ophthalmol. 2011, 25(5):355-357.
3. Alroy J., Sabnis S., Kopp J.B. Renal pathology in Fabry disease. J. Am. Soc. Nephrol. 2002, 13:5134-5138.
4. Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006, 580:5533-5540.
5. Arnal-Levron M., Chen Y., Delton-Vandenbrouke I., Luquine-Costaz C. Bis(monoacylglycerol)phosphate reduces oxysterol formation and apoptosis in macrophages exposed to oxidized LDL. Biochem. Pharmacol. 2013, 86(1):115-121.
6. Baronas E.T., Lee J.W., Alden C., Hsieh F.H. Biomarkers to monitor drug-induced phospholipidosis. Toxicol. Appl. Pharmacol. 2007, 218:72-78.
7. Barone L.R., Boyer S., Damewood J.R., Fikes J., Ciaccio P.J. Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than nonphospholipogenic pharmaceuticals in preclinical toxicology studies. J. Toxicol. 2012, 2012:308594.
8. Barr D.B., Wilder L.C., Caudill S.P., Gonzalez A.J., Needham L.L., Pirkle J.L. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ. Health Perspect. 2005, 113(2):192-200.
9. Berridge B.R., Chatman L.A., Odin M., Schultze A.E., Losco P.E., Meehan J.T., Peters T., Vonderfecht S.L. Letter to the editor. Toxicol. Pathol. 2007, 35:325.
10. Bertrand L., Baldet P., Blanc F., Puveo J. Cirrhogenic hepatitis due to perhexiline maleate: general review based upon one new case with ultrastructural study. Ann. Med. Interne 1978, 129(10):565-574.
11. Besley G.T., Elleder M. Enzyme activities and phospholipid storage patterns in brain and spleen samples from Niemann-Pick disease variants: a comparison of neuropathic and non-neuropathic forms. J. Inherit. Metab. Dis. 1986, 9:59-71.
12. Bolaños-Meade J., Zhou L., Hoke A., Corse A., Vogelsang G., Wagner K.R. Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease. Am. J. Hematol. 2005, 78(4):306-309.
13. Cartwright M.E., Petruska J., Arezzo J., Frank D., Litwak M., Morrissey R.E., MacDonald J., Davis T.E. Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects. Toxicol. Pathol. 2009, 37:902-910.
14. Chatman L.A., Morton D., Johnson T.O., Anway S.D. A strategy for risk management of drug-induced phospholipidosis. Toxicol. Pathol. 2009, 37:997-1005.
15. Chevallier J., Chamoun Z., Jiang G., Prestwich G., Sakai N., Parton R.G., Gruenberg J. Lysobisphosphatidic acid controls endosomal cholesterol levels. J. Biol. Chem. 2008, 283(41):27871-27880.
16. D'Amico D.J., Kenyon K.R., Rushkin J.N. Amiodarone keratopathy: drug-induced lipid storage disease. Arch. Opthalmol. 1981, 99(2):257-261.
17. Daniel W.A., Wo´jcikowski J. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol. Toxicol. 1997, 80:62-68.
18. Daniel W.A., Wo´jcikowski J. The role of lysosomes in the cellular distribution of thioridazine and potential drug interactions. Toxicol. Appl. Pharmacol. 1999, 158:115-124.
19. Dastur D.K., Thakkar B.K., Desai P.R. Experimental neurotoxicity of the anorectic fenfluramine. Acta Neuropathol. 1985, 67:142-154.
20. De Duve C., De Barsy T., Poole B., Trouet A., Tulkens P., Van Hoof F. Lysomotrophic agents. Biochem. Pharmacol. 1974, 23:2495-2531.
21. DeBroe M.E., Paulus G.J., Verpooten G.A., Roels F., Buyssens N., Wedeen R., Van Hoof F., Tulkens P.M. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int. 1984, 25(4):643-652.
22. Ferrara N., Corbi G., Capuano A., Filippelli A., Rossi F. Memantine-induced hepatitis with cholestasis in a very elderly patient. Ann. Intern. Med. 2008, 148(8):631-632.
23. Filippone E.J., Carson J.M., Beckford R.A., Jaffe B.C., Newman E., Awsare B.K., Doria C., Farber J.L. Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient. Transplant. Proc. 2011, 43(7):2792-2797.
24. Frish W., Lu¨llmann-Rauch R. Effects of several lipidosis-inducing drugs upon the area postrema and adjacent medullary nuclei of adult rats. Acta Neuropathol. 1980, 52:179-187.
25. Gallala H.D., Sandhoff K. Biological function of the cellular lipid BMP - BMP as a key activator for cholesterol sorting and membrane digestion. Neurochem. Res. 2011, 26(9):1594-1600.
26. Gonzalez-Rothi R.J., Zander D.S., Ros P.R. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest 1995, 107:1763-1765.
27. Griese M., Brasch F., Aldana V.R., Cabrera M.M., Goelnitz U., Ikonen E., Karam B.J., Liebisch G., Linder M.D., Lohse P., Meyer W., Schmitz G., Pamir A., Ripper J., Rolfs A., Schams A., Lezana F.J. Respiratory disease in Niemann-Pick type C2 is caused by pulmonary alveolar proteinosis. Clin. Genet. 2010, 77:119-130.
28. Hammond T.G., Majewski R.R., Kaysen J.H., Goda F.O., Navar G.L., Pontillon F., Verroust P.J. Gentamicin inhibits rat renal cortical homotypic endosomal fusion: role of megalin. Am. J. Physiol. Ren. Physiol. 1997, 272:F117-F123.
29. Harder A., Widjaja F., Debuch H. Studies on lipids from the liver and spleen of a child (O.L.) with Niemann-Pick's disease type. C. J. Clin. Chem. Clin. Biochem. 1984, 22(2):199-201.
30. Hirst L.W., Sanborn G., Green W.R., Miller N.R., Heath W.D. Amodiaquine ocular changes. Arch. Ophthalmol. 1982, 100(8):1300-1304.
31. Hook G.E.R. Alveolar proteinosis and phospholipidosis of the lungs. Toxicol. Pathol. 1991, 19:482-513.
32. Huang L.K., Tsai M.J., Tsai H.C., Chao H.S., Lin F.C., Change S.C. Statin-induced lung injury: diagnostic clue and outcome. Postgrad. Med. J. 2013, 89:14-19.
33. Ikeda K., Hirayama M., Hirota Y., Asa E., Seki J., Tanaka Y. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes (2008). Biochem. Biophys. Res. Commun. 2008, 377:268-274.
34. Jones C.J.P., Salisbury R.S., Jayson M.I.V. The presence of abnormal lysosomes in lymphocytes and neutrophils during chloroquine therapy: a quantitative ultrastructural study. Ann. Rheum. Dis. 1984, 43:710-715.
35. Joshi J.M., Rao P., Kodavanti S., Lockard V.G., Mehendale H.M. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim. Biophys. Acta 1989, 1004:309-320.
36. Jung H.J., Suzuki K. Morphological changes in CNS of rats treated with perhexiline maleate (Pexid). Acta Neuropathol. 1978, 42:159-164.
37. Kaufmann A.M., Krise J.P. Niemann-Pick type C1 functions in regulating lysosomal amine content. J. Biol. Chem. 2008, 283:24584-24593.
38. Khubchandani S.R., Bichle L.S. Hydroxychloroquine-induced phospholipidosis in a case of SLE: the wolf in zebra clothing. Ultrastruct. Pathol. 2013, 37(2):146-150.
39. Kobayashi T., Stang E., Fang K.S., de Moerloose P., Parton R.G., Gruenberg J. A lipid associated with the anitphospholipid syndrome regulates endosome structure and function. Nature 1998, 392(6672):193-197.
40. Koenig H., Goldstone A., Blume G., Lu C.Y. Testosterone-mediated sexual dimorphism of mitochondria and lysosomes in the mouse kidney proximal tubules. Science 1980, 209:1023-1026.
41. Kornhuber J., Tripal P., Reichel M., Mu¨hle C., Rhein C., Muehlbacher M., Groemer T.W., Gulbins E. Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell. Physiol. Biochem. 2010, 26:9-20.
42. Lantuejoul S., Brambilla E., Brambilla C., Devouassoux G. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur. Respir. J. 2002, 19(3):577-580.
43. Linhart A., Elliot P.M. The heart in Andreson-Fabry disease and other lysosomal storage disorders. Heart 2007, 93:528-535.
44. Lloyd-Evans E., Platt F.M. Lipids on trial: the search for the offending metabolite in Niemann-Pick type C disease. Traffic 2010, 11:419-428.
45. Locatelli-Hoops S., Remmel N., Klingenstein R., Breiden B., Rssocha M., Schoeniger M., Koenigs C., Saenger W., Sandhoff K. Saposin A mobilizes lipids from low cholesterol and high bis(monoacylglycerol)phosphate-containing membranes. J. Biol. Chem. 2006, 281:32451-32460.
46. Love S., Bridges L.R., Case C.P. Neurofibrillary tangles in Niemann-Pick disease type C. Brain 1995, 118(1):119-129.
47. Lu¨llmann H., Lu¨llmann-Rauch R., Wasserman O. Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 1978, 27:1103-1108.
48. Lu¨llmann-Rauch R. Lipidosis-like alterations in spinal cord and cerebellar cortex of rats treated with chlorphentermine or tricyclic anti-depressants. Acta Neuropathol. 1976, 35:55-67.
49. Luquain-Costaz C., Lefai E., Arnal-Levron M., Markina D., Sakai¨ S., Euthine V., Makina A., Guichardant M., Yamashita S., Kobayashi T., Lagarde M., Moulin P., Delton-Vandenbrouke I. Bis(monoacylglycerol)phosphate accumulation in macrophages induces intracellular cholesterol redistribution, attenuates liver-x receptor/ATP-binding cassette transporter A1/ATP-binding cassette transporter G1 pathway, and impairs cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1803-1811.
50. Matsuzawa Y., Yamamoto A., Adachi S., Nishikawa M. Studies on drug-induced lipidosis VIII. Correlation between drug accumulation and acidic phospholipids. J. Biochem. 1977, 82:1369-1377.
51. Maxfield F.R., Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005, 438:612-621.
52. Meiner V., Shpitzen S., Mandel H., Klar A., Ben-Neriah Z., Zlotogora J., Sagi M., Lossos A., Bargal R., Sury V., Carmi R., Leitersdorf E., Zeigler M. Clinical-biochemical correlation in molecularly characterized patients with Niemann-Pick type C. Genet. Med. 2001, 3:343-348.
53. Mesens N., Desmidt M., Verheyen G.R., Starckx S., Damsch S., De Vries R., Verhemeldonck M., Van Gompel J., Lampo A., Lammens L. Phospholipidosis in rats treated with amiodarone: serum biochemistry and whole genome micro-array analysis supporting the lipid traffic jam hypothesis and the subsequent rise of the biomarker BMP. Toxicol. Pathol. 2012, 40(3):491-503.
54. Millat G., Chikh K., Naureckiene S., Sleat D.E., Fensom A.H., Higaki K., Elleder M., Lobel P., Vanier V.T. Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am. J. Hum. Genet. 2001, 69:1013-1021.
55. Miyashita T., Ojima A., Tuji T., Tajima T., Watanabe K. Varied pulmonary lesions with intra-alveolar large lamellar bodies in an autopsy case with busulfan therapy. Acta Pathol. Jpn. 1977, 27(2):239-249.
56. Morissette G., Ammoury A., Rusu D., Marguery M.C., Lodge R., Poubelle P.E., Marceau F. Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. Br. J. Pharmacol. 2009, 157(8):1531-1540.
57. Mu¨ller-Ho¨cker J., Schmid H., Weiss M., Dendorfer U., Braun G.S. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry's disease: case report and review of the literature. Hum. Pathol. 2003, 34(3):285-289.
58. Muñoz S.J., Martinez-Hernandez A., Maddrey W.C. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology 1990, 12(2):342-347.
59. Nasveld P.E., Edstein M.D., Reid M., Brennan L., Harris I.E., Kitchener S.J., Leggat P.A., Pickford P., Kerr C., Ohrt C., Prescott W. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob. Agents Chemother. 2010, 54(2):792-798.
60. Papov V.V., Locke K.N., Mineo A.M., Johnson B., Huang Z., Stoltz J.H., Jayadev J.A., Phillips J.A. Development of an HPLC-MS method for tracking specific LBPA variants in biological matrices in response to drug-induced phospholipidosis. #O34. Presented at the Connecticut Separation Science Council 9th Annual Csaba Horva´th Medal Award Symposium 2009.
61. Park J.H., Schuchman E.H. Acid ceramidase in human disease. Biochim. Biophys. Acta 2006, 1758:2133-2138.
62. Parkinson-Lawrence E.J., Shandala T., Prodoehl M., Plew R., Borlace G.N., Brooks D.A. Lysosomal storage disease: revealing lysosomal function and physiology. Physiology 2010, 25:102-115.
63. Phillips J.A., Papov V.V., Stoltz J.H., Mineo A.M., Locke K.N., Jayadev S. Urinary LBPA tracks with onset and reversal of drug-induced phospholipidosis. Society of Toxicology Abstract Poster No. 724 2009.
64. Platt F.M., Boland B., van der Spoel A.C. Lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J. Cell Biol. 2012, 199(5):723-734.
65. Prasad A., Kaye E.M., Alroy J. Electron microscopic examination of skin biopsy as a cost-effective tool in the diagnosis of lysosomal storage diseases. J. Child Neurol. 1995, 11:301-308.
66. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 2006, 5(4):567-583.
67. Reaves B.J., Row P.E., Bright N.A., Luzio J.P., Davidson H.W. Loss of cation-independent mannose 6-phosphate receptor expression promotes accumulation of lysobisphosphatidic acid in multilamellar bodies. J. Cell Sci. 2000, 113:4099-4108.
68. Roos J.M., Aubry M.C., Edwards W.D. Chloroquine cardiotoxicity clinicopathologic features in three patients and comparison with three patients with Fabry disease. Cardiovasc. Pathol. 2002, 11:277-283.
69. Rouser G., Kritchevsky G., Knudson A.G., Simon G. Accumulation of glycerophospholipid in classical Niemann-Pick disease. Lipids 1968, 3(3):287-290.
70. Sadrieh N. The regulatory challenges of drug-induced phospholipidosis. Presented at the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (ACPS) 2010, (April).
71. Schmitz G., Mu¨ller G. Structure and function of lamellar bodies, lipid protein complexes involved in storage and secretion of cellular lipids. J. Lipid Res. 1991, 32:1539-1570.
72. Tengstrand E.A., Miwa G.T., Hsieh F.Y. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Expert. Opin. Drug Metab. Toxicol. 2010, 6(5):555-570.
73. Thomas G.H., Tuck-Muller C.M., Miller C.S., Reynolds L.W. Correction of sphingomyelinase deficiency in Niemann-Pick type C fibroblasts by removal of lipoprotein fraction from culture media. J. Inherit. Metab. Dis. 1989, 12(2):139-151.
74. Thompson K.L., Haskins K., Rosenzweig B.A., Stewart S., Zhang J., Peters D., Knapton A., Rouse R., Mans D., Colatsky T. Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat. Int. J. Toxicol. 2012, 31(1):14-24.
75. Thompson K.L., Zhang J., Stewart S., Rosenzweig B.S., Shea K., Mans D., Colatsky T. Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats. Toxicol. Lett. 2012, 213(2):285-291.
76. US F.D.A. Risk assessment of drug-induced phospholipidosis in the CNS. US FDA Project in Scientific Priority Areas 2009, (Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ScienceBoardtotheFoodandDrugAdministration/UCM152329.pdf).
77. Vejux A., Malvitte L., Lizard G. Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis. Braz. J. Med. Biol. Res. 2008, 41(7):545-556.
78. Webber S.K., Domniz Y., Sutton G.L., Rogers C.M., Lawless M.A. Corneal deposition after high-dose chloropromazine hydrochloride therapy. Cornea 2001, 20(2):217-219.
79. Weiss J.N., Weinberg R.S., Regelson W. Keratopathy after oral administration of tilorone hydrochloride. Am J. Ophthalmol. 1980, 89(1):46-53.
80. Willard J. FDA phospholipidosis working group preliminary results and developing opinions. Presented at the Society of Toxicology Pathology (STP) Continuing Education Course on Drug-Induced Phospholipidosis June 2008.
81. Willard J. FDA PLWG activities on phospholipidosis: data mining, modeling and laboratory research. Presented at the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting 2010, (April).
82. Wraith J.E., Baumgartner M.R., Bembi B., Covanis A., Levade T., Mengel E., Pineda M., Sedel F., Topc¸u M., Vanier M.T., Widner H., Wijburg F.A., Patterson M.C. Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol. Genet. Metab. 2009, 98(1-2):152-165.
83. Xu Z., Farver W., Kodukula S., Storch J. Regulation of sterol transport between membranes and NPC2. Biochemistry 2008, 47(42):11134-11143.
84. Yamamoto A., Adachi S., Kitani T., Shinji Y., Seki K. Drug-induced lipidosis in human cases and in animal experiments: accumulation of an acidic glycerophospholipid. J. Biochem. 1971, 69(3):613-615.
85. Yamamoto A., Adachi S., Ishikawa K., Yokomura T., Kitani T. Studies on drug-induced lipidosis: III. Lipid composition of the liver and some other tissues in clinical cases of "Niemann-Pick-like-syndrome" induced by 4,4'-diethylaminoethoxyhexesterol. J. Biochem. 1971, 70(5):775-784.
86. Yanjanin N.M., Ve´lez J.I., Gropman A., King K., Bianconi S.E., Conley S.K., Brewer C.C., Solomon B., Pavan W.J., Acros-Burgos M., Patterson M.C., Porter F.D. Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B(1):132-140.
87. Zinchuk O., Watanabe M., Hayashi N., Fukushima A., Ueno H. A case of tamoxifen keratopathy. Arch Opthalmol. 2006, 124(7):1046-1048.